Long-term ‘benefits’ of metformin in type 2 diabetes prevention
Metformin reduces the development of type 2 diabetes over 15 years, research published in Diabetes Care has shown.
People with a higher baseline fasting glucose or HbA1c and women with a history of gestational diabetes benefitted the most, according to the study funded by the National Institute of Diabetes and Digestive and Kidney Diseases.
Researchers from George Washington University examined records from America’s Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS) to explore the long-term the effects of metformin on type 2 diabetes prevention.
Summarising the results, the authors said: “During 15 years of postrandomisation follow-up, metformin reduced the incidence (by HR) of diabetes compared to placebo by 17% or 36% based on glucose or HbA1c levels, respectively. Metformin’s effect on the development of glucose-defined diabetes was greater for women with a history of prior gestational diabetes mellitus (GDM) (HR 0.59, RD −4.57 cases/100 person-years) compared with parous women without GDM (HR 0.94, RD −0.38 cases/100 person-years [interaction P = 0.03 for HR, P = 0.01 for RD]).
“Metformin also had greater effects, by HR and RD, at higher baseline fasting glucose levels. With diabetes development based on HbA1c, metformin was more effective in subjects with higher baseline HbA1c by RD, with metformin RD −1.03 cases/100 person-years with baseline HbA1c <6.0% (42 mmol/mol) and −3.88 cases/100 person-years with 6.0–6.4% (P = 0.0001).”
The researchers said: “Metformin reduces the development of diabetes over 15 years. The subsets that benefitted the most include subjects with higher baseline fasting glucose or HbA1c and women with a history of GDM [gestational diabetes].”
To view the study, click here.
Diet and exercise can also play a crucial role in type 2 diabetes prevention and management. The award-winning Low Carb Program, developed by Diabetes Digital Media (DDM), is achieving significant results in preventing, controlling and reserving type 2 diabetes. One-year outcomes reveal the average participant with type 2 diabetes loses 7.4kg and reduces their HbA1c by 1.2%, with 39% of people placing their HbA1c under the threshold for type 2 diabetes diagnosis.